{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:31:58Z","timestamp":1761561118964},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.hrthm.2006.12.027","type":"journal-article","created":{"date-parts":[[2006,12,23]],"date-time":"2006-12-23T12:14:17Z","timestamp":1166876057000},"page":"S88-S90","source":"Crossref","is-referenced-by-count":38,"special_numbering":"S","title":["Nonantiarrhythmic drug therapy for atrial fibrillation"],"prefix":"10.1016","volume":"4","author":[{"given":"Katherine T.","family":"Murray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa C.","family":"Mace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenjiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2006.12.027_bib1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nrd1876","article-title":"Drug therapy for atrial fibrillation: where do we go from here?","volume":"4","author":"Page","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hrthm.2006.12.027_bib2","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1460-9592.2003.00128.x","article-title":"Pharmacological prevention of atrial tachycardia induced atrial remodeling as a potential therapeutic strategy","volume":"26","author":"Shinagawa","year":"2003","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2006.12.027_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.pcad.2005.06.013","article-title":"New antiarrhythmic drugs for prevention of atrial fibrillation","volume":"48","author":"Goldstein","year":"2005","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.hrthm.2006.12.027_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.pcad.2005.06.014","article-title":"Electrical and structural remodeling: role in the genesis and maintenance of atrial fibrillation","volume":"48","author":"Schoonderwoerd","year":"2005","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.hrthm.2006.12.027_bib5","first-page":"21","article-title":"Mechanisms of atrial remodeling and clinical relevance","volume":"20","author":"Nattel","year":"2005","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.hrthm.2006.12.027_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pharmthera.2004.01.001","article-title":"Nonchannel drug targets in atrial fibrillation","volume":"102","author":"Goette","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.hrthm.2006.12.027_bib7","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.hrthm.2005.05.020","article-title":"Treatment and prevention of atrial fibrillation with non-antiarrhythmic pharmacologic therapy","volume":"2","author":"Lozano","year":"2005","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2006.12.027_bib8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.yjmcc.2004.11.015","article-title":"Rapid stimulation causes electrical remodeling in cultured atrial myocytes","volume":"38","author":"Yang","year":"2005","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.hrthm.2006.12.027_bib9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/eurheartj\/ehi645","article-title":"Is atrial fibrillation an inflammatory disorder?","volume":"27","author":"Boos","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2006.12.027_bib10","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/01.hco.0000231408.69307.9b","article-title":"Clinical trials, the renin angiotensin system and atrial fibrillation","volume":"21","author":"Birnie","year":"2006","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.hrthm.2006.12.027_bib11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/eurheartj\/ehi668","article-title":"Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence","volume":"27","author":"Ehrlich","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2006.12.027_bib12","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1161\/01.CIR.0000072793.81076.D4","article-title":"Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials","volume":"107","author":"Vermes","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2006.12.027_bib13","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ahj.2004.09.033","article-title":"Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)","volume":"149","author":"Maggioni","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.hrthm.2006.12.027_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ahj.2005.06.036","article-title":"Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program","volume":"152","author":"Ducharme","year":"2006","journal-title":"AM Heart J"},{"key":"10.1016\/j.hrthm.2006.12.027_bib15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/01.CIR.100.4.376","article-title":"Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction","volume":"100","author":"Pedersen","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2006.12.027_bib16","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","article-title":"Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End point reduction in hypertension (LIFE) study","volume":"45","author":"Wachtell","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2006.12.027_bib17","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.hrthm.2004.08.008","article-title":"Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM","volume":"1","author":"Murray","year":"2004","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2006.12.027_bib18","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.jacc.2004.11.070","article-title":"Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis","volume":"45","author":"Healey","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2006.12.027_bib19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1540-8167.2006.00477.x","article-title":"Aldosterone antagonism as an antiarrhythmic approach for atrial arrhythmias in heart failure","volume":"17","author":"Ram","year":"2006","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2006.12.027_bib20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2006.12.027_bib21","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2006.12.027_bib22","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2006.12.027_bib23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1540-8167.2006.00372.x","article-title":"Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure","volume":"17","author":"Shroff","year":"2006","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2006.12.027_bib24","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/eurheartj\/ehi350","article-title":"Inflammation in the genesis and perpetuation of atrial fibrillation","volume":"26","author":"Engelmann","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2006.12.027_bib25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijcard.2006.04.026","article-title":"The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation","volume":"115","author":"Korantzopoulos","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrthm.2006.12.027_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jtcvs.2004.09.014","article-title":"The effects of steroids on the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting surgery: a prospective randomized trial","volume":"130","author":"Prasongsukarn","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.hrthm.2006.12.027_bib27","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1161\/01.CIR.0000069566.78305.33","article-title":"Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils","volume":"107","author":"Leaf","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2006.12.027_bib28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.plipres.2006.02.004","article-title":"n-3 Fatty acids, cardiac arrhythmia and fatal coronary heart disease","volume":"45","author":"Brouwer","year":"2006","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.hrthm.2006.12.027_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/01.hco.0000221574.95383.6f","article-title":"Cardiac connexins as candidate genes for idiopathic atrial fibrillation","volume":"21","author":"Gollob","year":"2006","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.hrthm.2006.12.027_bib30","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1056\/NEJMoa052800","article-title":"Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation","volume":"354","author":"Gollob","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2006.12.027_bib31","article-title":"The association of human connexin 40 genetic polymorphisms with atrial fibrillation","author":"Juang","year":"2006","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrthm.2006.12.027_bib32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1161\/CIRCULATIONAHA.105.606251","article-title":"Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation","volume":"114","author":"Guerra","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2006.12.027_bib33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1540-8167.2005.40687.x","article-title":"The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress","volume":"16","author":"Haugan","year":"2005","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2006.12.027_bib34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1540-8167.2003.02381.x","article-title":"5-hydroxytryptamine and atrial fibrillation: how significant is this piece in the puzzle?","volume":"14","author":"Yusuf","year":"2003","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2006.12.027_bib35","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1161\/01.CIR.100.19.2010","article-title":"Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS-100302 in experimental atrial flutter and fibrillation","volume":"100","author":"Rahme","year":"1999","journal-title":"Circulation"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527106022752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527106022752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T14:53:43Z","timestamp":1547132023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527106022752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S1547527106022752"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2006.12.027","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}